Stockscreener 앱 받기
0.995
5.24%
-0.055
시간 외 거래:
1.00
0.005
+0.50%
전일 마감가:
$1.05
열려 있는:
$1.02
하루 거래량:
713.01K
Relative Volume:
0.83
시가총액:
$89.70M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.4716
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
-17.08%
1개월 성능:
-14.96%
6개월 성능:
-38.20%
1년 성능:
-19.11%
1일 변동 폭
$0.99
$1.06
1주일 범위
$0.99
$1.18
52주 변동 폭
$0.9204
$2.11
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
IMUX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.995 | 89.70M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital - Defense World
Immunic to present at AAN 2025 and German Biotech Days in April - Proactive Investors
Immunic, Inc. to Participate in Scientific and Industry Conferences in April - The Victoria Advocate
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic CMO discusses significance of MS Awareness Month; progress with treatment - Proactive Investors
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - Defense World
180 Life Sciences (NASDAQ:ATNF) versus Immunic (NASDAQ:IMUX) Head to Head Comparison - Defense World
Immunic (NASDAQ:IMUX) Now Covered by Analysts at William Blair - Defense World
Immunic (NASDAQ:IMUX) Now Covered by William Blair - The AM Reporter
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation - Nasdaq
William Blair sees Immunic stock outperforming on RMS therapy By Investing.com - Investing.com Australia
How did Immunic Inc (IMUX) fare last session? - uspostnews.com
William Blair sees Immunic stock outperforming on RMS therapy - Investing.com
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky - Yahoo Finance
William Blair Initiates Immunic at Outperform With $6.80 Price Target - MarketScreener
Buy Rating on Immunic Driven by Promising CALLIPER Study Outcomes and Market Opportunities in Progressive Multiple Sclerosis - TipRanks
Immunic’s Vidofludimus Calcium: A Promising Disruptor in the $45 Billion Multiple Sclerosis Market - TipRanks
StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell - Defense World
Immunic provides MS research update – ICYMI - Proactive Investors Australia
Immunic (NASDAQ:IMUX) Raised to “Hold” at StockNews.com - Defense World
Immunic at Leerink’s Conference: Strategic Moves in MS Treatment - Investing.com India
Immunic at Leerink’s Conference: Strategic Moves in MS Treatment By Investing.com - Investing.com South Africa
Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April - Proactive financial news
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts - Defense World
Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data - Proactive Investors
Immunic to Participate in Scientific and Investor Conferences in March - Kilgore News Herald
Immunic announces participation in Hamburg and Miami conferences - Proactive Investors USA
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Biotechs challenge big pharma with new oral weight loss therapies - Proactive Investors USA
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis - The Malaysian Reserve
Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum - Proactive Investors
Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum | NASDAQ:IMUX - Proactive financial news
Immunic (NASDAQ:IMUX) Receives Buy Rating from HC Wainwright - MarketBeat
How Do Things Look For Immunic Inc (NASDAQ: IMUX) In The Short-Term? - Stocks Register
Immunic's (IMUX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic (IMUX) to Release Earnings on Thursday - MarketBeat
Immunic drug candidate may offer new obesity treatmentICYMI - Proactive financial news
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week - Yahoo Finance
H.C. Wainwright maintains Immunic stock Buy rating, $10 target By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains Immunic stock Buy rating, $10 target - Investing.com
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - The Malaysian Reserve
Market movers: Walmart, Palantir, Immunic, Alibaba… - Proactive Investors UK
Immunic’s IMU-856 shows promise in weight management By Investing.com - Investing.com Nigeria
Immunic highlights IMU-856’s potential as weight management therapy - Proactive Investors Australia
Immunic's IMU-856 shows promise in weight management - Investing.com
Immunic’s IMU-856 shows promise for obesity treatment - Proactive Investors USA
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):